The efficacy and safety of a single dose of Clindesse vaginal cream versus a seven-dose regimen of Cleocin vaginal cream in patients with bacterial vaginosis. by Faro, Sebastian & Skokos, Campbell K
CLINICAL STUDY
The efﬁcacy and safety of a single dose of Clindesse
TM vaginal cream
versus a seven-dose regimen of Cleocin
1
vaginal cream in patients with
bacterial vaginosis
SEBASTIAN FARO
1 & CAMPBELL K. SKOKOS
2 FOR THE CLINDESSE
TM
INVESTIGATORS GROUP
1The Woman’s Hospital of Texas, Houston, Texas, and
2The Woman’s Clinic, Little Rock, Arkansas, USA
Abstract
Objective. To determine whether a single dose of Clindesse
TM vaginal cream is comparable in efﬁcacy and safety to
Cleocin
1
vaginal cream administered once daily for 7 days in the treatment of bacterial vaginosis.
Study design. This multicenter, randomized, single-blind, parallel-group study enrolled 540 patients with BV infections.
Treatment consisted of either a single intravaginal dose of Clindesse
TM or 7 daily doses of Cleocin
1
. Efﬁcacy and safety were
assessed 21–30 days after the start of treatment. The efﬁcacy endpoints were Investigator Cure, Clinical Cure (a composite
of all 4 Amsel’s criteria and Investigator Cure), Nugent Cure (Nugent score 54), and Therapeutic Cure (a composite of
Clinical Cure and Nugent Cure). Resolution of individual Amsel’s criteria was also evaluated. Treatment-emergent adverse
events were monitored throughout the study.
Results. There were no signiﬁcant differences in cure rates between the Clindesse
TM and Cleocin
1
treatment groups in
Investigator Cure (P=0.702), Clinical Cure (P=0.945), Nugent Cure (P=0.788), or Therapeutic Cure (P=0.572). Results
were also similar for 3 of 4 and 2 of 4 Amsel’s criteria and for each individual Amsel’s criterion (all P-values 40.200).
Ninety-ﬁve percent conﬁdence intervals for each endpoint were consistent with equivalence between the 2 products. There
was no signiﬁcant difference between the treatment groups in the incidence of treatment-emergent adverse events
(P=0.386).
Conclusions. A single dose of Clindesse
TM vaginal cream is equivalent in safety and efﬁcacy to a 7-dose regimen of Cleocin
1
vaginal cream in the treatment of bacterial vaginosis. This represents a signiﬁcant advance in the treatment of bacterial
vaginosis.
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Introduction
Bacterial vaginosis (BV) continues to be one of the
most common vaginal disorders in reproductive-age
women. It represents 40–50% of all cases of vaginitis,
surpassing both vaginal candidiasis and vaginal
trichomoniasis [1]. It causes signiﬁcant patient
discomfort and has been associated with many
disorders of the female reproductive tract, including
recurrent urinary tract infections, adnexal tender-
ness, postpartum endometritis, increased risk of
infection after gynecologic surgery, pelvic inﬂamma-
tory disease, and adverse pregnancy outcomes. BV
results from replacement of the normal Lactobacillus-
dominant vaginal ﬂora with polymicrobial, primarily
anaerobic, bacteria. The cause of this microbial shift
is not fully understood [2,3].
Recommended antimicrobial treatments for non-
pregnant women often include oral or intravaginal
therapy with clindamycin. While both oral and
intravaginal administrations are effective, intravagi-
nal medications may result in fewer of the adverse
side effects associated with oral antibiotic therapy
such as nausea, vomiting, and taste perversion [4,5].
In addition, patients treated with intravaginal thera-
pies report increased treatment satisfaction
compared with those treated with oral therapies
[6]. Most intravaginal therapies for BV, like oral
therapies, require the inconvenience of daily use for
multiple days, and this inconvenience may have a
negative effect on treatment compliance and satisfac-
tion [7]. Thus, an effective single-dose vaginal
treatment for BV might be beneﬁcial to women from
a number of different points of view.
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TM (clindamycin phosphate) vaginal
cream 2% is a single-dose intravaginal therapy
recently approved for use in the treatment of BV in
nonpregnant women. Clindesse
TM uses a patented,
sustained-release, single-dose, topical cream emul-
sion. In vitro studies with this cream technology have
shown that in an acetate buffer of pH 4.3, which
simulates normal vaginal ﬂuid, the sustained release
cream is highly stable and remains intact for a
prolonged period of time. Under the same condi-
tions, a conventional cream rapidly disintegrates and
releases the active ingredient into the medium (data
on ﬁle, KV Pharmaceutical Company, St. Louis,
Missouri). Clinical studies demonstrated that buto-
conazole nitrate 2% in this sustained-release
formulation remains in the vagina 63% longer than
butoconazole nitrate 2% in a conventional formula-
tion (median retention time 4.2 days versus 2.6 days)
[8].
Given the ability of Clindesse
TM to maintain
therapeutic levels of clindamycin in the vagina for a
prolonged period of time, we hypothesize that a
single dose of Clindesse
TM would be equivalent to a
7-day course of a conventional clindamycin phos-
phate intravaginal cream. Such reductions in dosing
frequency have been shown to increase treatment
compliance, patient satisfaction, and quality of life
[7]. Thus, the purpose of the current study was to
determine whether a single dose of Clindesse
TM is
equivalent in safety and efﬁcacy to a 7-day regimen of
Cleocin
1
vaginal cream in the treatment of BV.
Material and methods
The study was designed in accordance with the
United States Food and Drug Administration FDA
Center for Drug Evaluation and Research (CDER)
1998 draft guidelines for developing effective treat-
ments for BV [2]. This was a multicenter, single
(Investigator)-blind, active-controlled study. Patients
were recruited at 28 clinics in the United States, each
with its respective IRB/ethics board approval. All
patients provided signed informed consent before
any study-related procedure was performed.
Eligible patients were nonpregnant women at least
18 years of age with a clinical diagnosis of BV, which
was deﬁned as meeting all of Amsel’s criteria [9]
(520% clue cells, off-white [milky or gray], thin,
homogenous vaginal discharge, vaginal pH 44.5, a
ﬁshy amine odor upon the addition of 10% KOH to
vaginal ﬂuid [‘‘whiff’’ test]). Patients were excluded
if they were pregnant or nursing; had sexually
transmitted infections, had vulvovaginal infections
other than BV, had vulvovaginal or cervical abnorm-
alities or disorders; were actively menstruating; had
received antifungal or antimicrobial treatment within
14 days of the study; were using intrauterine devices
(IUDs); were taking anticoagulants, lithium, dis-
ulﬁram, or neuromuscular blocking agents; or were
hypersensitive to clindamycin, lincomycin, or to any
excipient in the drug formulation.
Eligible patients were randomly assigned to 1 of 2
treatment arms (Clindesse
TM or Cleocin
1
) in a single
(Investigator)-blind fashion according to a computer-
generated randomization schedule. Patients were
instructedintheappropriatestudymedicationadmin-
istration techniques, which were to be performed or
started within 48 hours after leaving the clinic.
Clindesse
TM vaginal cream consisted of 2%
clindamycin phosphate formulated in 5 g of the
sustained-release vaginal cream, for a total of 100 mg
clindamycin phosphate. Clindesse
TM was self-admi-
nistered by patients in a single dose. Cleocin
1
vaginal
cream also consisted of 2% clindamycin phosphate,
but formulated in 5 g of a conventional vaginal
cream. Cleocin
1
was self-administered by the patient
once daily for 7 consecutive days.
Treatment effectiveness was evaluated and com-
pared at a Test-Of-Cure (TOC) visit 21–30 days
following the start of treatment, using several clinical
and microbiologic indices. Investigator Cure was
based on the Investigator’s response (Yes/No) to a
question at the TOC visit regarding the need for
additional BV treatment. Clinical Cure was a
composite endpoint including resolution of all 4
Amsel’s criteria and Investigator Cure. Nugent Cure
was deﬁned as a Gram stain Nugent score [10] 54
(on a 10-point scale). Therapeutic Cure was a
composite endpoint deﬁned as both Clinical Cure
and Nugent Cure. In addition, the 4 Amsel’s criteria
were each evaluated individually. The TOC visit was
selected to demonstrate both status and duration of
outcome. The per-protocol (PP) population was
selected for the efﬁcacy analyses in accordance with
demonstration of equivalence between treatments.
The safety of the 2 treatments was evaluated by
monitoring treatment-emergent adverse events
(AEs) throughout the study.
Statistical methods
Efﬁcacy endpoints were analyzed using the center-
stratiﬁed Cochran-Mantel-Haenszel (CMH) esti-
mate of the difference in cure rates and
corresponding conﬁdence interval [11]. Clindesse
TM
was to be considered equivalent to Cleocin
1
if the 2-
sided 95% conﬁdence interval (CI) for the difference
in cure rates (Clindesse
TM minus Cleocin
1
) had a
lower limit greater than 720% and an upper limit
less than +20%. Efﬁcacy analyses were performed
using a PP population, which included patients who
administered study medication, had baseline Nugent
scores 54, had assessment results at the TOC visit
or discontinued participation in the study prior to the
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bial therapy for conditions other than BV during the
study, started study medication within 48 hours of
the entry visit, and had no major violations of the
study protocol. All patients who administered at least
1 dose of study medication were included in the
safety analyses.
Results
Of the 540 patients enrolled in the study (271 in the
Clindesse
TM group and 269 in the Cleocin
1
group),
253 (46.9%) were considered evaluable for the PP
population (128 in the Clindesse
TM group and 125
in the Cleocin
1
group). Of the 287 patients who were
not evaluable in the PP population, 92 had baseline
Nugent scores 54, 64 participated in the study for
less than 21 days but were not treatment failures, and
52 did not start study medication within 48 hours of
the Entry Visit. These 3 reasons account for
approximately 75% of the patients who were not
evaluable in the PP population. The percentages of
patients with each primary reason for non-evalu-
ability were similar between the treatment groups. A
complete listing of the primary reasons for non-
evaluability in the PP population by treatment group
is in Table I.
Cure of BV was evaluated by a number of different
measures. Frequencies of Investigator Cure, Clinical
Cure, Nugent Cure, and Therapeutic Cure are
presented in Table II.
The Investigator Cure represents the Investiga-
tor’s assessment of the need for additional therapy
for BV at the TOC Visit. Investigator Cure (no
additional therapy required for BV) was achieved in
89.1% of Clindesse
TM patients and 86.4% of
Cleocin
1
patients at the TOC visit. There were no
statistically signiﬁcant differences in Investigator
Cure rates between treatment groups (P=0.702)
and the 95% CIs for the differences were consistent
with equivalence with regard to the need for
additional treatment of BV as assessed by the
Investigator.
Clinical Cure, which represents both alleviation of
BV signs and symptoms and alleviation of the need
for additional BV therapy at the TOC visit, was
achieved in 64.3% of Clindesse
TM patients and
63.2% of Cleocin
1
patients. There were no statisti-
cally signiﬁcant differences in Clinical Cure rates
between treatment groups (P=0.945).
Similar cure rates were also observed in the 2
treatment groups when less stringent criteria were
used to deﬁne cure. If 3 of the 4 Amsel’s criteria are
used to deﬁne cure, 87.5% of Clindesse
TM patients
and 83.2% of Cleocin
1
patients are cured
(P=0.399). When 2 of the 4 Amsel’s criteria are
used to deﬁne cure, cure rates increase to 90.6% of
Clindesse
TM patients and 91.2% of Cleocin
1
pa-
tients (P=0.792). There were no statistically
signiﬁcant differences in cure rates between treat-
ment groups and the 95% CIs for the differences
were consistent with equivalence in the alleviation of
BV signs using both 2 and 3 of the 4 Amsel’s criteria.
In addition, there were no statistically signiﬁcant
differences in resolution of Amsel’s criteria between
the treatment groups when the criteria for clue cells
(520%) and a negative ‘‘whiff’’ test were evaluated
together (P=0.965) or when the criteria for clue
cells, ‘‘whiff’’ test, and vaginal pH (54.7) were
evaluated together (P=0.539). The cure rates
associated with each Amsel’s criterion and selected
groups of criteria are presented in Table III.
Table I. Primary reasons for non-evaluability in the per-protocol population by treatment group.
Clindesse
TM (N=271)
{ Cleocin
1
(N=269)
{ Overall
{ (N=540)
{
Reason n
§ (%)
§ n
§ (%)
§ n
§ (%)
§
Did not take study medication 8 (3.0) 4 (1.5) 12 (2.2)
Did not take Cleocin
1
on 3 consecutive days - - 18 (6.7) 18 (3.3)
Baseline Nugent score 54 42 (15.5) 50 (18.6) 92 (17.0)
Did not take study medication with 48 hours of the entry visit 34 (12.5) 18 (6.7) 52 (9.6)
Participated in the study for 521 days without treatment
failure
37 (13.7) 27 (10.0) 64 (11.9)
Received antimicrobial therapy for reasons other than bacterial
vaginosis
7 (2.6) 14 (5.2) 21 (3.9)
Used other intravaginal products or had intercourse within 7
days of start of treatment
11 (4.1) 9 (3.3) 20 (3.7)
Did not meet all inclusion and exclusion criteria 3 (1.1) 3 (1.1) 6 (1.1)
Participated in the study for 440 days 1 (0.4) 1 (0.4) 2 (0.4)
Total patients not evaluable 143 (52.8) 144 (53.5) 287 (53.1)
Total patients evaluable 128 (47.2) 125 (46.5) 253 (46.9)
{ ‘‘Overall’’ refers to the total number of patients enrolled;
{ Denotes total number of patients enrolled by and across treatment group;
§ n and
% denote the number and percentage of evaluable and nonevaluable patients by reason for each treatment group.
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diagnostic measure of BV. Nugent Cure (Nugent
score 54) was achieved in 56.5% of Clindesse
TM
patients and 57.7% of Cleocin
1
patients at the TOC
visit. There were no statistically signiﬁcant differ-
ences in Nugent Cure rates between treatment
groups (P=0.788) and the 95% CIs for the
differences were consistent with equivalence in
Nugent Cure rates at the TOC Visit.
Therapeutic Cure represents the composite of
Clinical Cure and Nugent Cure at the TOC visit.
Analysis results demonstrate that 53 (42.1%) patients
in the Clindesse
TM group achieved Therapeutic Cure
compared with 57 (45.6%) patients in the Cleocin
1
group. Therapeutic Cure results indicate that a single
dose of Clindesse
TM is statistically equivalent in
effectiveness to 7 daily doses of Cleocin
1
in the
treatment of BV (P=0.572).
Among the 263 patients in the Clindesse
TM group
and the 265 patients in the Cleocin
1
group that
received at least 1 dose of study medication, 80
Clindesse
TM-treated patients (30.4%) and 71 Cleo-
cin
1
-treated patients (26.8%) had a total of 115 and
97 treatment–emergent AEs, respectively, during the
study. The most commonly reported AEs are shown
in Table IV. Twenty-seven patients (10.3%) in the
Clindesse
TM group reported 29 study medication-
related AEs compared with 21 patients (7.9%) in the
Cleocin
1
group who reported 22 study medication-
related AEs. The number of patients who reported
AEs and study medication-related AEs were not
statistically different between the 2 treatment groups
(P=0.386 for overall AEs and P=0.336 for study
medication-related AEs). Overall, among the 528
patients who received study medication, 5 (0.9%)
were discontinued from the study due to AEs. Three
(1.1%) Clindesse
TM-treated patients were discon-
tinued due to Vaginal Yeast Infection, Candidiasis,
and Allergic Reaction to Study Drug (1 patient
each). Two patients (0.8%) in the Cleocin
1
group
were discontinued due to Vaginal Yeast Infections.
There was 1 serious AE (cellulitis) reported by a
patient receiving Cleocin
1
during the study. The
event was judged to be unrelated to the study
medication by the investigator.
Discussion
As we hypothesized, analyses of interpretive, symp-
tomatic, and diagnostic efﬁcacy variables revealed no
statistically signiﬁcant differences between use of
clindamycin phosphate 2%, administered in a single-
dose vaginal cream (Clindesse
TM), and in a standard
7-day vaginal cream (Cleocin
1
).
Investigator Cure is an interpretive measure
representing the requirement for additional therapy
Table II. Efﬁcacy outcomes at the Test-of-Cure Visit (number and % of evaluable patients cured).
Clindesse
TM Cleocin
1
Treatment differences
§
Endpoint N
{ n (%)
{ N
{ n (%
{) % 95% CI P-value
Investigator Cure 128 114 (89.1) 125 108 (86.4) 2.7 [75.4, 10.7] 0.702
Clinical Cure
| 126 81 (64.3) 125 79 (63.2) 1.1 [710.8, 13.0] 0.945
Nugent Score 54 124 70 (56.5) 123 71 (57.7) 71.3 [713.6, 11.1] 0.788
Therapeutic Cure
| 126 53 (42.1) 125 57 (45.6) 73.5 [715.8, 8.7] 0.572
{ Denotes the number of patients with non-missing data in each treatment group;
{ n and % denote the number and percentage of patients
cured within each endpoint for each treatment group;
§ Clindesse
TM minus Cleocin
1
cure rates;
| Subjects were considered evaluable
(included in N) and to have achieved cure if data for 1 Amsel’s criterion were missing, but all other criteria were consistent with cure.
Table III. Number and percent of patients with resolution of individual Amsel’s criteria at the Test-of-Cure Visit.
Clindesse
TM Cleocin
1
Treatment difference
§
Endpoint N
{ n (%)
{ N
{ n (%)
{ % 95% CI P-value
3 of 4 Amsel’s criteria resolved 128 112 (87.5) 125 104 (83.2) 4.3 [74.4, 13.0] 0.399
2 of 4 Amsel’s criteria resolved 128 116 (90.6) 125 114 (91.2) 70.6 [77.7, 6.5] 0.792
520% Clue cells 128 112 (87.5) 125 105 (84.0) 3.5 [75.1, 12.1] 0.480
Negative ‘‘whiff’’ test 128 116 (90.6) 125 118 (94.4) 73.8 [710.2, 2.7] 0.205
Normal discharge 128 108 (84.4) 125 108 (86.4) 72.0 [710.7, 6.7] 0.545
pH 54.7 127 94 (74.0) 122 87 (71.3) 2.7 [78.4, 13.8] 0.668
Clue cells + ‘‘whiff’’ test 128 108 (84.4) 125 105 (84.0) 0.4 [78.6, 9.4] 0.965
Clue cells + ‘‘whiff’’ test + pH 127 87 (68.5) 122 79 (64.8) 3.7 [78.0, 15.5] 0.539
{ Denotes the number of patients with non-missing data in each treatment group;
{ n and % denote the number and percentage of patients
cured within each endpoint for each treatment group;
§ Clindesse
TM minus Cleocin
1
cure rates.
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Investigator. Clinical Cure is a conservative sympto-
matic measure representing resolution of all 4 of the
Amsel’s criteria as well as a favorable assessment of
cure by the Investigator. The Nugent score repre-
sents a diagnostic evaluation of BV that is not often
used in clinical practice. Therapeutic Cure, which
requires both Clinical Cure and Nugent Cure,
represents a very conservative composite outcome
combining symptomatic, interpretive, and diagnostic
measures of BV that has not previously been used as
an endpoint. The deﬁnitions of Clinical Cure and
Therapeutic Cure used here are considerably more
conservative than deﬁnitions used in previous
studies. Although these more conservative criteria
for cure are compliant with the 1998 CDER
guidance for the evaluation of BV in clinical studies,
they may result in lower cure rates than reported in
previous studies.
Resolution of 3 of the 4 Amsel’s criteria may be
more representative of the evaluation of BV in
clinical practice. Cure rates using this endpoint were
comparable between the Clindesse
TM and Cleocin
1
groups. A study evaluating a 7-day dosing regimen
with Cleocin
1
and a 7-day, twice-daily dosing
regimen with MetroGel
1
(0.75% metronidazole)
vaginal gel deﬁned BV cure as resolution in this
manner and reported 86.2% and 75.0% cure rates
for Cleocin
1
and MetroGel
1
, respectively [5].
Although there may be some differences between
these studies (e.g., study populations, inclusion
criteria, patient evaluability), the cure rates observed
were comparable to the 87.5% and 83.2% rates
observed using the same deﬁnition of cure with
Clindesse
TM and Cleocin
1
, respectively, in this
study. Previous clinical studies performed with
Cleocin
1
deﬁned BV cure as resolution of 2 of
Amsel’s criteria (the ‘‘whiff’’ test and clue cell
criteria) and reported a cure rate of 86% for a 7-
day dosing regimen [12]. This is comparable to the
84.4% and 84.0% cure rates observed using these 2
criteria with Clindesse
TM and Cleocin
1
, respectively,
in this study.
In the study reported here, there were no
signiﬁcant differences in the incidence of AEs
between the treatment groups, and AEs commonly
associated with oral therapy (e.g., nausea, taste
perversion) were reported in less than 1% of the
patients in either treatment group.
Conclusions
Overall, a single-dose regimen of Clindesse
TM was
shown to be comparable with respect to both efﬁcacy
and safety to Cleocin
1
. Clindesse
TM, however,
provides equivalent efﬁcacy and safety in a single
dose, compared with a 7-dose regimen of Cleocin
1
.
It has been shown that reducing dose frequency
increases the patient’s compliance with treatment,
symptom control, satisfaction with treatment, and
quality of life in a number of disease states [7].
Clindesse
TM offers these advantages, and therefore
represents an important therapeutic advance in the
treatment of BV.
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